(Q36283822)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16219011%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

review article

1 reference

title

Treating insulin resistance in type 2 diabetes with metformin and thiazolidinediones (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16219011%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

0 references

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16219011%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

author name string

Bailey CJ

series ordinal

1

1 reference

13 August 2017

1 November 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16219011%20AND%20SRC:MED&resulttype=core&format=json

Diabetes, Obesity and Metabolism

7 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16219011%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

volume

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16219011%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16219011%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

page(s)

675-691

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16219011%20AND%20SRC:MED&resulttype=core&format=json

Global and societal implications of the diabetes epidemic

7 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00497.X

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00497.X

Oral antihyperglycemic therapy for type 2 diabetes: scientific review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00497.X

Insulin signalling and the regulation of glucose and lipid metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00497.X

Insulin action and insulin resistance in human skeletal muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00497.X

Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00497.X

Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00497.X

Diabetes mellitus and diabetes-associated vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00497.X

Pharmacologic therapy for type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00497.X

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00497.X

British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00497.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00497.X

Insulin resistance and its treatment by thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00497.X

Peroxisome proliferator-activated receptors: nuclear control of metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00497.X

PPAR-gamma agonists: therapeutic role in diabetes, inflammation and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00497.X

The mechanisms of action of PPARs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00497.X

Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00497.X

Thiazolidinediones: metabolic actions in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00497.X

Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00497.X

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00497.X

Beta-cell rejuvenation with thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00497.X

Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00497.X

The effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00497.X

Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00497.X

Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00497.X

Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00497.X

Rosiglitazone reduces urinary albumin excretion in type II diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00497.X

Effects of pioglitazone in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00497.X

Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00497.X

Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00497.X

Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00497.X

Metformin: intrinsic vasculoprotective properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00497.X

To: Pothmann R, et al: Evaluation of applied kinesiology in nutritional intolerance of childhood. Forsch Komplementärmed Klass Naturheilkd 2001;8:336-344

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00497.X

Relation of metformin treatment to clinical events in diabetic patients undergoing percutaneous intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00497.X

Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00497.X

Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00497.X

Peroxisome proliferator-activated receptor-γ agonists in atherosclerosis: current evidence and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00497.X

The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00497.X

Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00497.X

Treatment with rosiglitazone reduces hyperinsulinemia and improves arterial elasticity in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00497.X

Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00497.X

Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00497.X

The hormone resistin links obesity to diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00497.X

Evidence for a potent antiinflammatory effect of rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00497.X

The anti-inflammatory and potential anti-atherogenic effect of insulin: a new paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00497.X

Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00497.X

Metformin in non-alcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00497.X

Descriptive review of the evidence for the use of metformin in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00497.X

Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00497.X

Gemfibrozil considerably increases the plasma concentrations of rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00497.X

Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00497.X

Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00497.X

Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00497.X

Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00497.X

Thiazolidinediones, Peripheral Edema, and Type 2 Diabetes: Incidence, Pathophysiology, and Clinical Implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00497.X

Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00497.X

Metformin-associated lactic acidosis: a rare or very rare clinical entity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00497.X

Experiences of a poison center with metformin-associated lactic acidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00497.X

Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00497.X

Adverse events with concomitant use of simvastatin or atorvastatin and thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00497.X

10.1111/J.1463-1326.2005.00497.X

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16219011%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

1 reference